Logo image of BMEA

BIOMEA FUSION INC (BMEA) Stock Fundamental Analysis

NASDAQ:BMEA - Nasdaq - US09077A1060 - Common Stock - Currency: USD

3.98  +0.05 (+1.27%)

After market: 4.17 +0.19 (+4.77%)

Fundamental Rating

2

Taking everything into account, BMEA scores 2 out of 10 in our fundamental rating. BMEA was compared to 572 industry peers in the Biotechnology industry. BMEA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BMEA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BMEA had negative earnings in the past year.
In the past year BMEA has reported a negative cash flow from operations.
In the past 5 years BMEA always reported negative net income.
In the past 5 years BMEA always reported negative operating cash flow.
BMEA Yearly Net Income VS EBIT VS OCF VS FCFBMEA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

BMEA's Return On Assets of -130.42% is on the low side compared to the rest of the industry. BMEA is outperformed by 82.30% of its industry peers.
Looking at the Return On Equity, with a value of -189.55%, BMEA is doing worse than 68.50% of the companies in the same industry.
Industry RankSector Rank
ROA -130.42%
ROE -189.55%
ROIC N/A
ROA(3y)-48.11%
ROA(5y)-110.57%
ROE(3y)-55.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BMEA Yearly ROA, ROE, ROICBMEA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 0 0 0 0

1.3 Margins

BMEA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMEA Yearly Profit, Operating, Gross MarginsBMEA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

BMEA has more shares outstanding than it did 1 year ago.
BMEA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BMEA Yearly Shares OutstandingBMEA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
BMEA Yearly Total Debt VS Total AssetsBMEA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -5.86, we must say that BMEA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.86, BMEA is not doing good in the industry: 65.49% of the companies in the same industry are doing better.
There is no outstanding debt for BMEA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.86
ROIC/WACCN/A
WACCN/A
BMEA Yearly LT Debt VS Equity VS FCFBMEA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.39 indicates that BMEA has no problem at all paying its short term obligations.
The Current ratio of BMEA (3.39) is comparable to the rest of the industry.
BMEA has a Quick Ratio of 3.39. This indicates that BMEA is financially healthy and has no problem in meeting its short term obligations.
BMEA's Quick ratio of 3.39 is in line compared to the rest of the industry. BMEA outperforms 42.30% of its industry peers.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 3.39
BMEA Yearly Current Assets VS Current LiabilitesBMEA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BMEA have decreased strongly by -20.06% in the last year.
EPS 1Y (TTM)-20.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BMEA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.23% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.8%
EPS Next 2Y0.5%
EPS Next 3Y3.25%
EPS Next 5Y14.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMEA Yearly Revenue VS EstimatesBMEA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
BMEA Yearly EPS VS EstimatesBMEA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BMEA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BMEA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMEA Price Earnings VS Forward Price EarningsBMEA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMEA Per share dataBMEA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.5%
EPS Next 3Y3.25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BMEA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMEA FUSION INC

NASDAQ:BMEA (2/4/2025, 8:00:01 PM)

After market: 4.17 +0.19 (+4.77%)

3.98

+0.05 (+1.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2024-10-29/amc
Earnings (Next)N/A N/A
Inst Owners64.87%
Inst Owner Change0.01%
Ins Owners15.37%
Ins Owner Change0.23%
Market Cap144.24M
Analysts81.33
Price Target30.86 (675.38%)
Short Float %45.2%
Short Ratio14.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.89%
Min EPS beat(2)5.7%
Max EPS beat(2)6.07%
EPS beat(4)2
Avg EPS beat(4)-2.14%
Min EPS beat(4)-12.83%
Max EPS beat(4)6.07%
EPS beat(8)4
Avg EPS beat(8)-0.55%
EPS beat(12)5
Avg EPS beat(12)-2.88%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-31.64%
PT rev (3m)-30.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-26.72%
EPS NY rev (1m)0%
EPS NY rev (3m)0.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.9
P/tB 1.9
EV/EBITDA N/A
EPS(TTM)-4.01
EYN/A
EPS(NY)-3.43
Fwd EYN/A
FCF(TTM)-3.12
FCFYN/A
OCF(TTM)-3.11
OCFYN/A
SpS0
BVpS2.1
TBVpS2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -130.42%
ROE -189.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.11%
ROA(5y)-110.57%
ROE(3y)-55.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 3.39
Altman-Z -5.86
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)546.57%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.75%
EPS Next Y-14.8%
EPS Next 2Y0.5%
EPS Next 3Y3.25%
EPS Next 5Y14.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-31.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.19%
EBIT Next 3Y-16.59%
EBIT Next 5Y-13.81%
FCF growth 1Y-92.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.95%
OCF growth 3YN/A
OCF growth 5YN/A